Impact of diabetic polyneuropathy and cardiovascular autonomic neuropathy on the excretion of urinary 8-epi-PGF_2α and its metabolites (2, 3-dinor and 2, 3-dinor-5, 6-dihydro)

References

• Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004; 25: 612–628
   PubMed Web of Science ®Google Scholar
• Low PA, Lagerlund TD, McManis PG. Nerve blood flow and oxygen delivery in normal, diabetic, and ischemic neuropathy. Int Rev Neurobiol 1989; 31: 355–438
   PubMed Web of Science ®Google Scholar
• Low PA, Nickander KK. Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 1991; 40: 873–877
   PubMed Web of Science ®Google Scholar
• Kihara M, Nickander KK, Low PA. The effect of aging on endoneurial blood flow, hyperemic response and oxygen-free radicals in rat sciatic nerve. Brain Res 1991; 18:562: 1–5
   Google Scholar
• Lowitt S, Malone JI, Salem AF, Korthals J, Benford S. Acetyl-l-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism 1995; 44: 677–680
   PubMed Web of Science ®Google Scholar
• Nagamatsu M, Schmelzer JD, Zollman PJ, Smithson IL, Nickander KK, Low PA. Ischemic reperfusion causes lipid peroxidation and fiber degeneration. Muscle Nerve 1996; 19: 37–47
   PubMedGoogle Scholar
• Nickander KK, Schmelzer JD, Rohwer DA, Low PA. Effect of alpha-tocopherol deficiency on indices of oxidative stress in normal and diabetic peripheral nerve. J Neurol Sci 1994; 126: 6–14
   PubMed Web of Science ®Google Scholar
• Nagamatsu M, Nickander KK, Schmelzer JD, Raya A, Wittrock DA, Tritschler H, Low PA. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160–1167
   PubMed Web of Science ®Google Scholar
• Obrosova IG, Fathallah L, Lang HJ, Greene DA. Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: A prevention study. Diabetologia. 1999; 42: 1187–1194
   PubMed Web of Science ®Google Scholar
• Obrosova IG, Fathallah L, Stevens MJ. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp Neurol 2001; 172: 211–219
   PubMed Web of Science ®Google Scholar
• Stevens MJ, Obrosova IG, Cao X, Van Huysen C, Greene DA. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2002; 49: 1006–10015
   Google Scholar
• Low PA, Nickander KK, Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997; 46(Suppl. 2)38–42
   Web of Science ®Google Scholar
• Hermenegildo C, Raya A, Roma J, Romero FJ. Decreased glutathione peroxidase activity in sciatic nerve of alloxan-induced diabetic mice and its correlation with blood glucose levels. Neurochem Res 1993; 18: 893–896
   PubMed Web of Science ®Google Scholar
• Kishi Y, Schmelzer JD, Yao JK, Zollman PJ, Nickander KK, Tritschler HJ, Low PA. Alpha-lipoic acid: Effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes 1999; 48: 2045–2051
   PubMed Web of Science ®Google Scholar
• Obrosova IG, Minchenko AG, Marinescu V, Fathallah L, Kennedy A, Stockert CM, Frank RN, Stevens MJ. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 2001; 44: 1102–1110
   PubMed Web of Science ®Google Scholar
• van Dam PS. Oxidative stress and diabetic neuropathy: Pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2002; 18: 176–184
   PubMed Web of Science ®Google Scholar
• Ziegler D, Sohr CG, Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 2004; 27: 2178–2183
   PubMed Web of Science ®Google Scholar
• Gopaul NK, Anggard EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz-Zadeh J. Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 1995; 368: 225–229
   PubMed Web of Science ®Google Scholar
• Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, Blumberg JB. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 59: 1960–1966
   PubMed Web of Science ®Google Scholar
• Morrow JD, Roberts LJ. The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 1995; 51: 1–9
   Google Scholar
• Roberts LJ, Morrow JD. The generation and actions of isoprostanes. Biochim Biophys Acta 1995; 1345: 121–135
   Google Scholar
• Basu S. Isoprostanes:Novel bioactive products of lipid peroxidation. Free Radic Res 2004; 38: 105–122
   PubMed Web of Science ®Google Scholar
• Nourooz-Zadeh J, Cooper MB, Ziegler D, Betteridge DJ. Urinary 8-epi-PGF2α and its endogenous beta-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total body oxidative stress. Biochem Biophys Res Commun 2005; 330: 731–736
   PubMed Web of Science ®Google Scholar
• The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26(Suppl. 1)5–20
   PubMedGoogle Scholar
• Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O'Brien PC, Melton LJ, Service FJ. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817–824
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Melton LJ, O'Brien PC, Service FJ. Approaches to improve epidemiological studies of diabetic neuropathy: Insights from the Rochester Diabetic Neuropathy Study. Diabetes 1997; 46: 5–8
   Google Scholar
• Ziegler D. Diagnosis and treatment of diabetic autonomic neuropathy. Curr Diab Rep 2001; 1: 216–227
   PubMedGoogle Scholar
• Nourooz-Zadeh J, Gopaul NK, Barrow S, Mallet AI, Anggard EE. Analysis of F2-isoprostanes as indicators of non-enzymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry: Development of a solid-phase extraction procedure. J Chromatogr B Biomed Appl 1995; 667: 199–208
   PubMed Web of Science ®Google Scholar
• Bruckdorfer KR. Lipid oxidation products and vascular function. Free Radic. Res. 1998; 28: 573–581
   PubMed Web of Science ®Google Scholar
• Obrosova IG. How does glucose generate oxidative stress in peripheral nerve?. Int Rev Neurobiol 2002; 50: 3–35
   PubMedGoogle Scholar
• Chiabrando C, Valagussa A, Rivalta C, Durand T, Guy A, Zuccato E, Villa P, Rossi JC, Fanelli R. Identification and measurement of endogenous beta-oxidation metabolites of 8-epi-Prostaglandin F2α. J Biol Chem 1999; 274: 1313–1319
   PubMedGoogle Scholar
• Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin F2α and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224–229
   PubMed Web of Science ®Google Scholar
• Devaraj S, Hirany SV, Burk RF, Jialal I. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin Chem 2001; 47: 1974–1979
   PubMed Web of Science ®Google Scholar
• Falardeau P, Oates JA, Brash AR. Quantitative analysis of two dinor urinary metabolites of prostaglandin I2. Anal Biochem 1981; 115: 359–367
   PubMed Web of Science ®Google Scholar
• Fischer S, Scherer B, Weber PC. Prostacyclin metabolism in adults and neonates. Urinary profiles of 6-ketoprostaglandin F1 alpha and 2, 3-dinor-6-ketoprostaglandin F1 alpha studied by gas chromatography-mass spectrometry. Biochim Biophys Acta 1983; 750: 127–133
   PubMedGoogle Scholar
• FitzGerald GA, Brash AR, Falardeau P, Oates JA. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest 1981; 68: 1272–1275
   PubMed Web of Science ®Google Scholar
• FitzGerald GA, Maas RL, Lawson JA, Oates JA, Roberts LJ, Brash AR. Aspirin inhibits endogenous prostacyclin and thromboxane biosynthesis in man. Adv Prostaglandin Thromboxane Leukot Res 1983; 11: 265–266
   PubMedGoogle Scholar
• Vesterqvist O, Green K. Development of a GC-MS method for quantitation of 2, 3-dinor-6-keto-PGF1 alpha and determination of the urinary excretion rates in healthy humans under normal conditions and following drugs. Prostaglandins 1984; 28: 139–154
   PubMedGoogle Scholar
• Barrow SE, Ward PS, Sleightholm MA, Ritter JM, Dollery CT. Cigarette smoking: profiles of thromboxane- and prostacyclin-derived products in human urine. Biochim Biophys Acta 1989; 993: 121–127
   PubMed Web of Science ®Google Scholar
• Ritter JM, Cockcroft JR, Doktor HS, Beacham J, Barrow SE. Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man. Br J Clin Pharmacol 1989; 28: 573–579
   PubMedGoogle Scholar
• Wennmalm A. Formation of prostacyclin during administration of beta 1-selective and non-selective beta-adrenergic antagonists in healthy humans. Clin Physiol 1992; 12: 107–115
   PubMedGoogle Scholar
• Riutta A, Nurmi E, Weber C, Hansson G, Vapaatalo H, Mucha I. Selective solid-phase extraction of urinary 2,3-dinor-6-ketoprostaglandin F1 alpha for determination with radioimmunoassay. Anal Biochem 1994; 220: 351–359
   PubMedGoogle Scholar